Xcout Intel
Metsera competitors & alternatives
The 12 closest competitors and alternatives to Metsera among drug discovery companies — ranked by similarity to what Metsera actually does, not by market-cap band.
Subscribe to see Metsera’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Metsera
Metsera, Inc. is a clinical-stage biopharmaceutical company traded on the NASDAQ under the symbol MTSR, with its headquarters located in New York, New York, focusing on next-generation obesity and metabolic portfolios.
Metsera at a glance
Metsera is a drug discovery company headquartered in United States. It has raised at least $505M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $215M in November 2024. Xcout tracks 15 named people at Metsera, including Christopher Whitten Bernard (Chief Executive Officer).
Metsera leadership
- Christopher Whitten BernardChief Executive Officer
- Clive Meanwellinitial CEO
- Whit BernardCo-Founder and current CEO
- Brian HubbardExecutive Officer
- Brian J. HubbardExecutive Officer
- Christopher J. VisioliExecutive Officer
9 more named people on record for Metsera, with roles, board committees and tenure — see the full roster →
Metsera funding rounds
At least $505M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $215M | 6 named | |
| Series A | $290M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Metsera competitors
Ranked by semantic similarity — how close each company is to Metsera by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biopharmaceuticals
Vogenx, Inc. is a clinical-stage biopharmaceutical and life science company that discovers and develops novel therapeutics to treat metabolic and gastrointestinal diseases, including post-bariatric hypoglycemia and gastroparesis. Its lead drug candidate, mizagliflozin, is an oral small molecule designed to inhibit SGLT1, reducing glucose absorption and the secretion of insulin and gastric inhibitory peptide.
Similar drug discovery company
Bridge Medicines LLC is a drug discovery holding company headquartered in New York, NY, that accelerates the path of therapeutic pipelines from research to patients.
Similar drug discovery company
Raziel Therapeutics is a clinical-stage pharmaceutical company founded in 2012 and headquartered in Rehovot, Israel. The company originated from proprietary technology and collaborates internationally on medical treatments, including fat reduction therapeutics.
Similar drug discovery company
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Similar drug discovery company
Caldera Therapeutics, Inc. is a Cambridge, Massachusetts-based clinical-stage biotechnology company focused on treatments such as a bispecific inflammatory bowel disease (IBD) asset.
Similar drug discovery company
META Pharmaceuticals Inc. is a pioneering biotechnology company focusing on immuno-metabolism and gastrointestinal therapeutics within immunology, operating research efforts connected to JLABS in Shanghai.
Similar drug discovery company
Astria Therapeutics, Inc. is a public biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to developing life-changing therapies for patients.
Similar drug discovery company
Kainova Therapeutics, formerly known as Domain Therapeutics, is a clinical-stage biopharmaceutical company headquartered in Montreal, Quebec. The company drives a clinical pipeline of advanced GPCR-modulating therapies to address unmet medical needs.
Similar drug discovery company
Axovia Therapeutics is a privately held biotechnology company headquartered in London, England. The firm leads the development of innovative gene therapies designed to treat genetic forms of blindness and obesity associated with ciliopathies. It operates in the life sciences sector with a dedicated team of researchers.
Similar drug discovery company
Aneira Pharma, Inc. is a privately held pharmaceutical company founded in 2008 with its headquarters in San Diego, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Metsera and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Metseraand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →